Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone
Brief Summary: The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CP 690,550 1 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 15 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 1 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 15 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 3 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 20 mg QD | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate

Answer: C